Form 4: Lemaitre Vascular Exec Boosts Equity Holdings

Lemaitre Vascular's Senior VP of Operations, Trent G. Kamke, acquired 1,177 restricted stock units and 7,222 stock options.

Summary

• Trent G. Kamke, Senior V. P., Operations at Lemaitre Vascular Inc. (LMAT), acquired 1,177 shares of common stock in the form of a restricted stock unit (RSU) award on December 10, 2025.
• The RSU award vests on a time-based schedule: 25% vests on December 1, 2026, with the remaining balance vesting in equal annual installments over the subsequent three years.
• The RSU award includes a provision for the withholding of shares by the Issuer to cover withholding taxes due on each vesting date.
• Kamke also acquired 7,222 stock options (right to buy) on December 10, 2025, with an exercise price of $83.66 per share.
• These stock options vest over a four-year period, with 25% vesting on the first anniversary of the grant date (December 10, 2026), and the balance vesting in equal annual installments over the remaining three years.
• The stock options have an expiration date of December 10, 2032.
• Following these transactions, Kamke beneficially owns 4,660 shares of common stock directly and 7,222 stock options directly.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of executive interests with shareholders through equity grants, which is generally viewed favorably as it incentivizes long-term performance.

Positives

• The acquisition of restricted stock units and stock options by a Senior VP of Operations indicates a strong alignment of management's long-term interests with those of shareholders.
• Equity grants are a common form of executive compensation designed to incentivize performance and retention.

Future Outlook

The equity grants to the Senior VP of Operations suggest a long-term commitment to the company's future performance, as the awards vest over several years and align the executive's financial interests with future stock price appreciation.

Industry Context

Executive equity compensation, including restricted stock units and stock options, is a standard practice across various industries, particularly in the medical device and healthcare sectors where long-term innovation and market growth are key drivers.

Stakeholder Impact

• Shareholders: Increased alignment of executive compensation with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: Standard executive compensation practices can influence overall company morale and compensation structures.

Next Steps

• Vesting of 25% of the restricted stock units on December 1, 2026, with subsequent annual installments.
• Vesting of 25% of the stock options on December 10, 2026, with subsequent annual installments.

Key Dates

Keywords

Lemaitre Vascular, LMAT, Insider Transaction, Executive Compensation, Restricted Stock Unit, RSU, Stock Option, Equity Grant, Beneficial Ownership